4DMedical Ltd (AU:4DX)
ASX:4DX
4DX Stock Chart & Stats
AU$5.64
<AU$0.01(1.02%)
At close: 4:00 PM EST
AU$5.64
<AU$0.01(1.02%)
Day’s Range― - ―
52-Week RangeAU$0.23 - AU$7.55
Previous CloseN/A
Volume497.15K
Average Volume (3M)10.77M
Market Cap
AU$3.32B
Enterprise ValueAU$3.19B
Total Cash (Recent Filing)AU$56.76M
Total Debt (Recent Filing)AU$6.42M
Price to Earnings (P/E)―
Beta2.07
Next Earnings
Aug 27, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding589,363,600
10 Day Avg. Volume5,850,211
30 Day Avg. Volume10,774,582
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.80
Price to Sales (P/S)8.81
P/FCF Ratio-1.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.75Price Target Upside-33.51% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-0.16
Revenue Forecast (FY)AU$8.53M
Bulls Say, Bears Say
Bulls Say
Proprietary XV Technology Platform4DMedical’s XV Technology is a proprietary, clinically oriented lung imaging platform that produces quantitative ventilation/perfusion outputs. As protected, specialized diagnostic software, it creates durable product differentiation and licensing opportunities across hospitals, research and pharma trials, supporting longer-term commercial adoption and higher switching costs versus commodity imaging tools.
Diversified Recurring Revenue ModelThe company’s revenue model—software licensing/subscriptions, per-scan fees, services and collaboration agreements—provides multiple, complementary monetization streams. Recurring licenses and per-use scaling with scan volumes support predictability and upside as installed base grows, making revenue less binary and enabling long-term cash generation if adoption increases.
Conservative Leverage And Equity FinancingA relatively low debt-to-equity ratio and stable equity ratio reduce financial risk while the business scales. Lower leverage preserves flexibility to fund commercialization, regulatory work or partnerships without immediate liquidity pressure, giving management durable optionality to support growth initiatives or absorb shocks during a multi-year adoption curve.
Bears Say
Declining Revenue GrowthA -6.1% revenue decline indicates the company has not yet achieved consistent market traction. Persistent top-line contraction undermines scale economics and delays attainment of profitable margins, limiting the firm’s ability to invest in sales, integration and clinical evidence—critical drivers for longer-term adoption in hospitals and health systems.
Negative Operating And Free Cash FlowOperating and free cash flow are negative, forcing reliance on external funding to sustain operations and commercialization. Even with slight free-cash-flow improvement, continued cash burn constrains investment in sales, integrations and trials; recurring financing or equity raises could dilute shareholders and slow long-term scaling.
Persistent Losses And Negative ROESustained net losses and negative ROE show the business has yet to convert high gross margins into profitability after operating costs. Until operating margins improve and ROE turns positive, the firm may struggle to attract large institutional partners and justify long-term capital allocation absent clear path to profitable scale.
4DMedical Ltd News
4DX FAQ
What was 4DMedical Ltd’s price range in the past 12 months?
4DMedical Ltd lowest share price was AU$0.23 and its highest was AU$7.55 in the past 12 months.
What is 4DMedical Ltd’s market cap?
4DMedical Ltd’s market cap is AU$3.32B.
When is 4DMedical Ltd’s upcoming earnings report date?
4DMedical Ltd’s upcoming earnings report date is Aug 27, 2026 which is in 146 days.
How were 4DMedical Ltd’s earnings last quarter?
4DMedical Ltd released its earnings results on Feb 26, 2026. The company reported -AU$0.259 earnings per share for the quarter, missing the consensus estimate of -AU$0.036 by -AU$0.223.
Is 4DMedical Ltd overvalued?
According to Wall Street analysts 4DMedical Ltd’s price is currently Overvalued.
Does 4DMedical Ltd pay dividends?
4DMedical Ltd does not currently pay dividends.
What is 4DMedical Ltd’s EPS estimate?
4DMedical Ltd’s EPS estimate is -0.04.
How many shares outstanding does 4DMedical Ltd have?
4DMedical Ltd has 589,363,600 shares outstanding.
What happened to 4DMedical Ltd’s price movement after its last earnings report?
4DMedical Ltd reported an EPS of -AU$0.259 in its last earnings report, missing expectations of -AU$0.036. Following the earnings report the stock price went up 7.527%.
Which hedge fund is a major shareholder of 4DMedical Ltd?
Currently, no hedge funds are holding shares in AU:4DX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
4DMedical Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
AU$3.75 (-33.51% Downside)
AU$3.75 (-33.51% Downside)
Blogger Sentiment
Bullish
AU:4DX Sentiment 91%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth AU$9.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
205.21%
12-Months-Change
Fundamentals
Return on Equity
-890.76%
Trailing 12-Months
Asset Growth
36.79%
Trailing 12-Months
Company Description
4DMedical Ltd
4DMedical Limited operates as a medical technology company in Australia and the United States. It commercializes XV Technology, a four-dimensional lung imaging technology. The company also offers software as a service delivery model; XV lung ventilation analysis software; Permetium, a preclinical imaging system which quantify regional changes in pulmonary function; and AccuVent 200, a small animal ventilator. The company was incorporated in 2012 and is based in Carlton, Australia.
4DX Stock 12 Month Forecast
Average Price Target
AU$3.75
▼(-33.51% Downside)
Technical Analysis
Impedimed Limited
―
Cyclopharm Limited
―
Micro-X Ltd.
―
Aroa Biosurgery Ltd
―
EMvision Medical Devices Ltd.
―
Options Prices
Currently, No data available
---